Demant sees window of opportunity as millions lack hearing aids due to Covid-19
New products have driven Demant’s 2021 growth, but this was just the beginning. The Covid-19 pandemic has made the normally predictable hearing aid market unpredictable, but Demant wants to capitalize on the pent-up demand.
by christian bundgaard, translated by catherine brett
For hearing aid manufacturers, 2020 and 2021 were like chalk and cheese.
This is demonstrated at Demant, which has just released its financial results for 2021, boasting its best-ever operating result.
A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.
Bavarian Nordic’s smallpox vaccine, Jynneos, hasn’t yet been approved for monkeypox in Europe, a fact that hasn’t stopped countries there from lining up to secure vaccine supplies in light of the recent outbreak.